非小细胞肺癌血清血小板衍生生长因子BB水平及其诊断和治疗监测价值  

Diagnostic and therapeutic monitoring value of serum platelet-derived growth factor BB level in non-small cell lung cancer

作　　者：朱梅[1] 姜海英[1] 谢晓东[1] 李倩[1] 吕姣[1] Zhu Mei;Jiang Haiying;Xie Xiaodong;Li Qian;Lyu Jiao(Department of Medical Oncology,Xuzhou Cancer Hospital of Jiangsu Province,Xuzhou 221005,China)

机构地区：[1]江苏省徐州市肿瘤医院肿瘤内科,221005

出　　处：《肿瘤研究与临床》2020年第9期613-617,共5页Cancer Research and Clinic

基　　金：国家"十二五"科技支撑计划(2013BAI06B04H008);徐州市科技局项目(KC16SL117)。

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者血清中血小板衍生生长因子BB(PDGF-BB)水平在诊断和治疗监测中的临床意义。方法收集2014年10月至2017年12月在江苏省徐州市肿瘤医院接受治疗的111例NSCLC患者和同期在南京易安门诊部体检的105名健康对照者血液样本,采用Luminex法测定NSCLC患者和健康人血清中PDGF-BB水平以及采用铂类药物化疗后患者血清PDGF-BB的水平。应用受试者工作特征曲线(ROC)评估患者血清PDGF-BB水平对NSCLC的诊断价值,分析血清PDGF-BB水平与NSCLC患者临床病理特征及铂类药物化疗之间的关系。结果与健康对照者相比,NSCLC患者血清PDGF-BB水平降低[(54±24)ng/ml比(125±61)ng/ml,t=11.09,P<0.01]。血清PDGF-BB水平对NSCLC诊断的ROC下面积为0.890。不同性别、年龄及是否淋巴结转移NSCLC患者间,血清PDGF-BB水平差异均无统计学意义(均P>0.05);TNM分期高者血清PDGF-BB水平低于分期低者,分化程度低者血清PDGF-BB水平低于分化高者,差异均有统计学意义(均P<0.05)。在以铂类药物为基础的治疗后,NSCLC患者血清PDGF-BB水平持续降低。结论NSCLC患者血清PDGF-BB水平降低,其在NSCLC早期诊断方面具有一定的临床意义。Objective To investigate the clinical significance of the serum platelet-derived growth factor BB(PDGF-BB)level in the diagnosis and treatment monitoring of non-small cell lung cancer(NSCLC)patients.Methods Serum samples of 111 NSCLC patients in Xuzhou Cancer Hospital of Jiangsu Province and 105 healthy controls from Outpatients Department of Nanjing Yian Medical Examination Center between October 2014 and December 2017 were collected.Luminex assay was used to determine PDGF-BB level in serum samples of NSCLC patients and the healthy controls as well as patients after platinum chemotherapy.Receiver operating characteristic curve(ROC)was used to evaluate the diagnostic value of serum PDGF-BB level in patients with NSCLC,and the relationship of serum PDGF-BB level with clinicopathological features of NSCLC patients and platinum chemotherapy and effect was analyzed.Results Compared to the healthy controls,serum PDGF-BB level was decreased in NSCLC patients[(54±24)ng/ml vs.(125±61)ng/ml,t=11.09,P<0.01],and the area under the ROC of serum PDGF-BB level on the diagnosis of NSCLC was 0.890.There were no significant differences in serum PDGF-BB level among NSCLC patients with different gender,age or lymph node metastasis(all P>0.05);the serum PDGF-BB level in patients with high TNM stage was lower than that in patients with low TNM stage,and the serum PDGF-BB level in patients with low differentiation degree was lower than that in patients with high differentiation degree(all P<0.05).Serum PDGF-BB level was continued to decrease in NSCLC patients after treatment with platinum-based chemotherapy.Conclusion Serum PDGF-BB level of NSCLC patients is decreased,and it has a certain clinical significance in the early diagnosis of NSCLC.

关 键 词：血小板源性生长因子 癌 非小细胞肺 诊断 血小板衍生生长因子BB 铂类药物 

分 类 号：R734.2[医药卫生—肿瘤]